Stock LSPR LARR HEALPAR
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

LARR HEALPAR Stock

Equities

LSPR

US51724W1071

Chart LARR HEALPAR

Dynamic Chart

Latest news about LARR HEALPAR

Larkspur Acquisition Completes Merger With ZyVersa Therapeutics MT
Larkspur Health Acquisition Corp.(NasdaqGM:LSPR) dropped from NASDAQ Composite Index CI
Larkspur Health Acquisition Corp. announced that it has received $8.635 million in funding CI
ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction. CI
Larkspur Health Acquisition Corp. has Changed its Name to ZyVersa Therapeutics, Inc CI
Larkspur Health Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Larkspur Health Acquisition Refiles Registration Statement for Business Combination Agreement With ZyVersa Therapeutics MT
Larkspur Health Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
ZyVersa Therapeutics to Merge with Larkspur Health Acquisition, Obtain Nasdaq Listing MT
Larkspur Health Acquisition Corp. announced that it expects to receive $7 million in funding CI
ZyVersa Therapeutics, Inc. executed a confidential non -binding term sheet to acquire Larkspur Health Acquisition Corp. in a reverse merger transaction for approximately $190 million. CI
Certain Class B Common Stock of Larkspur Health Acquisition Corp. are subject to a Lock-Up Agreement Ending on 20-JUN-2022. CI
Larkspur Health Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Larkspur Health Acquisition Corp. Reports Earnings Results for the Nine Months Ended December 31, 2021 CI
Larkspur Health Acquisition Corp. Auditor Raises 'Going Concern' Doubt CI
More news

Press releases LARR HEALPAR

ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA") PR
LARKSPUR HEALTH ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K) AQ
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit PR
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc. PR
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
More press releases

Company Profile

Larkspur Health Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on companies in the biotechnology sector in the United States. The Company is not engaged in any business operations and has not generated any revenue.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. LSPR Stock